SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 06/26/2019
Entire Document
 

 

exclude items required by GAAP, such as certain reclassifications, eliminations, accruals, valuations and disclosures. The Monthly Operating Report also relates to periods which are different from the historical periods required in the Company’s reports pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Cautionary Statements Regarding Trading in the Company’s Securities

 

The Company’s stockholders are cautioned that trading in the Company’s securities during the pendency of the Chapter 11 process will be highly speculative and will pose substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 process. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

 

Limitation on Incorporation by Reference

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 is being furnished for informational purposes only and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this current report (including Exhibit 99.1 attached hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.

 

Additional Information regarding the Chapter 11 Case

 

Additional information about the Chapter 11 process and proposed asset sale, as well as other documents related to the restructuring and reorganization proceedings, is available through the Company’s claims and noticing agent Prime Clerk at https://cases.primeclerk.com/pernix. Information contained on, or that can be accessed through, such web site or the Court’s web site is not part of this Current Report.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are being filed herewith: 

     

Exhibit

No.

 

Document

   
2.1   Order Confirming Third Amended Joint Plan of Liquidation of Pernix Sleep, Inc.
99.1   Monthly Operating Report, dated June 11, 2019.